• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Aspirin-Free Strategies After Complex PCI: Type of P2Y Inhibitor Matters.

作者信息

Gragnano Felice, Calabrò Paolo

机构信息

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Caserta, Italy; Division of Clinical Cardiology, Azienda Ospedaliera di Rilievo Nazionale "Sant'Anna e San Sebastiano," Caserta, Italy.

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Caserta, Italy; Division of Clinical Cardiology, Azienda Ospedaliera di Rilievo Nazionale "Sant'Anna e San Sebastiano," Caserta, Italy.

出版信息

JACC Cardiovasc Interv. 2024 May 13;17(9):1131-1133. doi: 10.1016/j.jcin.2024.03.026.

DOI:10.1016/j.jcin.2024.03.026
PMID:38749593
Abstract
摘要

相似文献

1
Aspirin-Free Strategies After Complex PCI: Type of P2Y Inhibitor Matters.复杂经皮冠状动脉介入治疗后的无阿司匹林策略：P2Y 抑制剂类型很重要。
JACC Cardiovasc Interv. 2024 May 13;17(9):1131-1133. doi: 10.1016/j.jcin.2024.03.026.
2
Reply: Navigating the Role of Ticagrelor in Elective Complex PCI: Time to Rule Out or Reassess?
JACC Cardiovasc Interv. 2024 Apr 22;17(8):1070. doi: 10.1016/j.jcin.2024.03.018.
3
Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.替格瑞洛单药治疗与替格瑞洛联合阿司匹林治疗冠心病患者时的血小板抑制作用（TEMPLATE研究）：一项随机对照试验的研究方案
Trials. 2017 Nov 9;18(1):529. doi: 10.1186/s13063-017-2277-9.
4
Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial.替格瑞洛单药治疗糖尿病患者经皮冠状动脉介入治疗：来自TWILIGHT试验的见解。
Cardiovasc Res. 2020 Jun 1;116(7):e70-e72. doi: 10.1093/cvr/cvaa120.
5
Navigating the Role of Ticagrelor in Elective Complex PCI: Time to Rule Out or Reassess?
JACC Cardiovasc Interv. 2024 Apr 22;17(8):1069. doi: 10.1016/j.jcin.2024.02.029.
6
Omitting aspirin in PCI patients: Myth or reality?经皮冠状动脉介入治疗（PCI）患者中阿司匹林的应用：是误区还是现实？
Cardiovasc Drugs Ther. 2019 Dec;33(6):711-724. doi: 10.1007/s10557-019-06916-7.
7
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.在伴有和不伴有阿司匹林的强效口服 P2Y 受体抑制剂治疗的既往心肌梗死患者中，沃拉帕沙的药效学作用：VORA-PRATIC 研究结果。
J Am Heart Assoc. 2020 Apr 21;9(8):e015865. doi: 10.1161/JAHA.120.015865. Epub 2020 Apr 20.
8
Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.替格瑞洛在经皮冠状动脉介入治疗的糖尿病患者中的疗效和安全性：一项随机对照试验的荟萃分析。
J Cardiovasc Pharmacol. 2021 May 1;77(5):536-543. doi: 10.1097/FJC.0000000000000995.
9
Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.替格瑞洛或普拉格雷在接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中的应用。
Circulation. 2020 Dec 15;142(24):2329-2337. doi: 10.1161/CIRCULATIONAHA.120.050244. Epub 2020 Oct 29.
10
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial.复杂经皮冠状动脉介入治疗术后1个月以上阿司匹林与氯吡格雷单药治疗的比较：STOPDAPT-3试验的预先设定亚组分析
Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):198-209. doi: 10.1093/ehjcvp/pvaf002.

引用本文的文献

1
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial.急性冠状动脉综合征后替格瑞洛单药治疗：来自ULTIMATE-DAPT试验的经验教训。
Future Cardiol. 2024;20(11-12):591-593. doi: 10.1080/14796678.2024.2388472. Epub 2024 Aug 12.